Kalpesh Patel, Principal Medical Science Liaison – Precision Oncology at Labcorp, shared on LinkedIn:
“Not all HRD results are built the same way.
Labcorp’s OmniSeq INSIGHT includes comprehensive detection via BRCA1/2 mutation analysis and a Genomic Instability Score incorporating loss of heterozygosity (LOH), large-scale state transitions (LST), and telomeric allelic imbalance (TAI).
In CAP TODAY this month, Dr. Kyle Strickland of Labcorp Oncology, and Dr. Tricia Numan of Roswell Park Comprehensive Cancer Center discuss this approach in detail.
A GIS-based approach captures more patients who benefit from PARP inhibitors than LOH alone.”
Clues, questions in HR deficiency testing
Other articles about HRD on OncoDaily.